Foretinib (GSK1363089): Multikinase Inhibitor for Cancer Cell Growth and Motility Research

Executive Summary: Foretinib (GSK1363089) is a small-molecule, ATP-competitive inhibitor with sub-nanomolar potency against Met, KDR (VEGFR2), and other receptor tyrosine kinases (RTKs) relevant for angiogenesis and tumor progression (Schwartz 2022). This compound exhibits strong in vitro and in vivo efficacy in suppressing cancer cell proliferation, migration, invasion, and metastasis across multiple tumor models (APExBIO product page). It is highly soluble in DMSO (≥31.65 mg/mL) but insoluble in water and ethanol, supporting flexible assay design (APExBIO). Foretinib induces G2/M cell cycle arrest and blocks HGF-induced cell motility in diverse cancer cell lines. The recommended working concentration for cell-based assays is 0.25–1.5 μM, with maximal inhibition typically at 1 μM after 48 hours (Schwartz 2022).

Biological Rationale

Receptor tyrosine kinases (RTKs) such as VEGFRs and Met/HGFR are critical mediators of tumor angiogenesis, growth, and metastatic dissemination. Aberrant VEGF and HGF/Met signaling pathways drive cancer cell proliferation, migration, and neovascularization. Multikinase inhibitors like Foretinib disrupt these pathways by targeting multiple RTKs, providing a comprehensive blockade of oncogenic signaling (Schwartz 2022). Foretinib’s broad kinase inhibition profile makes it a strategic tool for preclinical models, especially where resistance to single-target inhibitors is observed. The compound is applicable across diverse cancer types, including melanoma, prostate, lung, colon, liver, and ovarian cancers (APExBIO).

Mechanism of Action of Foretinib (GSK1363089)

Foretinib (GSK1363089) is an ATP-competitive inhibitor of multiple RTKs. Its primary targets include:

• Met (HGFR): IC50 = 0.4 nM
• KDR (VEGFR2): IC50 = 0.9 nM
• Tie-2: IC50 = 1.1 nM
• VEGFR3/FLT4: IC50 = 2.8 nM
• RON: IC50 = 3 nM
• Additional inhibition of Flt-1, KIT, Flt-3, PDGFRα, PDGFRβ

By competitively binding the ATP site of these kinases, Foretinib blocks downstream phosphorylation events essential for cell proliferation and motility. The inhibition of HGF/Met and VEGF/VEGFR signaling suppresses angiogenesis, cell survival, and metastatic potential (Schwartz 2022). Foretinib also induces G2/M cell cycle arrest, leading to reduced cell division and tumor growth.

Evidence & Benchmarks

• Foretinib inhibits Met kinase activity with an IC50 of 0.4 nM in cell-free biochemical assays (APExBIO).
• Inhibits VEGFR2 (KDR) in vitro with an IC50 of 0.9 nM (Schwartz 2022).
• Blocks HGF-induced cell motility and induces G2/M arrest at 1 μM after 48 hours in A549, B16F10, and SK-HEP1 cells (Schwartz 2022).
• Suppresses tumor growth and metastasis in murine xenograft models (30 mg/kg oral dose) (Schwartz 2022).
• Demonstrates solubility ≥31.65 mg/mL in DMSO, supporting a range of in vitro dosing regimens (APExBIO).

For a scenario-driven, data-backed approach to Foretinib use in viability and proliferation assays, see this guide, which addresses reproducibility challenges; this article updates those recommendations with 2022 data from Schwartz.

For advanced mechanistic insights, this piece synthesizes translational strategy, while the current article expands on workflow integration and practical limits.

Applications, Limits & Misconceptions

Foretinib is intended solely for scientific research and not for clinical or diagnostic use. Applications include:

• In vitro proliferation, viability, and cytotoxicity assays in cancer cell lines.
• Migration and invasion assays to assess motility inhibition.
• In vivo xenograft models for anti-tumor and anti-metastatic efficacy.

Common Pitfalls or Misconceptions

• Foretinib is not water- or ethanol-soluble; improper solvent use reduces activity (APExBIO).
• Not recommended for use beyond 1.5 μM in cell assays due to cytotoxicity unrelated to RTK inhibition (Schwartz 2022).
• Results from one cancer model may not generalize; always validate in the target cell type.
• Not a diagnostic or therapeutic agent for human use; research-only reagent as per APExBIO.
• Batch-to-batch DMSO solubility may vary; verify prior to critical experiments.

For practical scenarios and troubleshooting, see this resource—the current article clarifies upper concentration limits and cross-model interpretation.

Workflow Integration & Parameters

• Formulation & Storage: Supplied as a solid; dissolve in DMSO at ≥31.65 mg/mL. Store solid and solutions at -20°C; use solutions promptly or within several months for consistent results (APExBIO).
• Working Range: For cell-based assays, use 0.25–1.5 μM. Maximal inhibition at 1 μM after 48 hours incubation (Schwartz 2022).
• Assay Types: Viability (e.g., MTT, CellTiter-Glo), proliferation, migration, invasion, and cell cycle assays.
• Model Systems: Validated in B16F10 melanoma, PC-3 prostate, A549 lung, HT29 colon, SK-HEP1 liver, SKOV3ip1, and HeyA8 ovarian cancer cell lines.
• Animal Studies: 30 mg/kg oral dosing reduces tumor burden and metastasis in mouse xenograft models.

For ordering, technical data, and product support, see the Foretinib (GSK1363089) A2974 kit from APExBIO.

Conclusion & Outlook

Foretinib (GSK1363089) delivers robust, reproducible inhibition of VEGFR and HGF/Met RTKs, making it a valuable agent for dissecting angiogenesis and metastasis in preclinical cancer research. Its favorable potency, solubility, and broad model validation support adoption across translational oncology workflows. Researchers should adhere to validated concentrations and solvent guidelines to maximize data quality. Future studies may clarify Foretinib's role in resistance models and combinatorial regimens.